NUDEXTA® (dextromethorphan and quinidine sulfate) capsule

LENGTH OF AUTHORIZATION: UP TO SIX MONTHS

REVIEW CRITERIA:

INITIATION OF THERAPY:
- Patient must be ≥ 18 years old.
- Must have a diagnosis of Pseudobulbar affect (PBA) secondary to a neurologic disorder (eg. ALS, MS, Parkinson’s disease, a stroke, traumatic brain injury…).
- Documentation of the secondary neurologic disorder must be submitted
- Must be prescribed or recommended by a specialist (If prescriber is not a specialist then the referral notes of the specialist must be submitted.)

CONTINUATION OF THERAPY (applies only after an initial authorization has been made by Florida Medicaid):
- Patient must be ≥ 18 years old.
- Must have a diagnosis of Pseudobulbar affect (PBA) related to a neurologic disorder (eg. ALS, MS, Parkinson’s disease, a stroke, traumatic brain injury…).
- Progress notes or medical records must demonstrate effectiveness of therapy

DOSING:
Starting dose: One capsule daily by mouth for 7 days.
Maintenance dose: After 7 days, 1 capsule every 12 hours.